JP2022515193A5 - - Google Patents

Info

Publication number
JP2022515193A5
JP2022515193A5 JP2021536024A JP2021536024A JP2022515193A5 JP 2022515193 A5 JP2022515193 A5 JP 2022515193A5 JP 2021536024 A JP2021536024 A JP 2021536024A JP 2021536024 A JP2021536024 A JP 2021536024A JP 2022515193 A5 JP2022515193 A5 JP 2022515193A5
Authority
JP
Japan
Prior art keywords
nucleotides
nucleotide
app
double
rnai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021536024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067449 external-priority patent/WO2020132227A2/en
Publication of JP2022515193A publication Critical patent/JP2022515193A/ja
Publication of JP2022515193A5 publication Critical patent/JP2022515193A5/ja
Priority to JP2024090554A priority Critical patent/JP2024113043A/ja
Pending legal-status Critical Current

Links

JP2021536024A 2018-12-19 2019-12-19 アミロイド前駆体タンパク質（ＡＰＰ）ＲＮＡｉ薬剤組成物およびその使用方法 Pending JP2022515193A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024090554A JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質（ＡＰＰ）ＲＮＡｉ薬剤組成物およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862781774P 2018-12-19 2018-12-19
US62/781,774 2018-12-19
US201962862472P 2019-06-17 2019-06-17
US62/862,472 2019-06-17
US201962928795P 2019-10-31 2019-10-31
US62/928,795 2019-10-31
PCT/US2019/067449 WO2020132227A2 (en) 2018-12-19 2019-12-19 AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024090554A Division JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質（ＡＰＰ）ＲＮＡｉ薬剤組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2022515193A JP2022515193A (ja) 2022-02-17
JP2022515193A5 true JP2022515193A5 (https=) 2022-12-26

Family

ID=71101909

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536024A Pending JP2022515193A (ja) 2018-12-19 2019-12-19 アミロイド前駆体タンパク質（ＡＰＰ）ＲＮＡｉ薬剤組成物およびその使用方法
JP2024090554A Pending JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質（ＡＰＰ）ＲＮＡｉ薬剤組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024090554A Pending JP2024113043A (ja) 2018-12-19 2024-06-04 アミロイド前駆体タンパク質（ＡＰＰ）ＲＮＡｉ薬剤組成物およびその使用方法

Country Status (20)

Country Link
US (2) US11034957B2 (https=)
EP (1) EP3898979A4 (https=)
JP (2) JP2022515193A (https=)
KR (1) KR20210111780A (https=)
CN (2) CN113454222B (https=)
AU (1) AU2019405783B2 (https=)
BR (1) BR112021011895A2 (https=)
CA (1) CA3124090A1 (https=)
CL (1) CL2021001605A1 (https=)
CO (1) CO2021009163A2 (https=)
CR (1) CR20210393A (https=)
DO (2) DOP2021000126A (https=)
IL (1) IL283852A (https=)
MX (1) MX2021007570A (https=)
MY (1) MY206230A (https=)
PE (1) PE20211420A1 (https=)
PH (1) PH12021551482A1 (https=)
SG (1) SG11202105886QA (https=)
TW (1) TW202039844A (https=)
WO (1) WO2020132227A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6382800B2 (ja) 2012-05-29 2018-08-29 スリーエム イノベイティブ プロパティズ カンパニー ポリマー発泡体及び中間体を含む吸収性物品
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein
US20220275037A1 (en) * 2019-07-19 2022-09-01 Dingding MO ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF
JP2019213978A (ja) * 2019-09-30 2019-12-19 株式会社三洋物産 遊技機
CA3189922A1 (en) * 2020-07-28 2022-02-03 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression
WO2022026531A1 (en) * 2020-07-29 2022-02-03 Alnylam Pharmaceuticals, Inc. Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases
US20240117349A1 (en) * 2021-01-29 2024-04-11 Alnylam Pharmaceuticals, Inc. iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP)
US20240175028A1 (en) * 2021-03-05 2024-05-30 Alnylam Pharmaceuticals, Inc DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA
TW202308662A (zh) * 2021-05-11 2023-03-01 美商黛瑟納製藥公司 用於靶定中樞神經系統的神經元之脂質結合物
EP4399311A4 (en) * 2021-09-10 2025-11-26 Alnylam Pharmaceuticals Inc APP ARNI COMPOSITIONS AND THEIR METHODS OF USE FOR TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ENLARGED ENDOSOMES
TW202328449A (zh) 2021-09-24 2023-07-16 美商艾拉倫製藥公司 微管相關蛋白ＴＡＵ（ＭＡＰＴ）ｉＲＮＡ試劑組合物及其使用方法
EP4422699A4 (en) * 2021-10-28 2026-02-11 Univ Hong Kong Science & Tech CRISPR-MEDIATED MANIPULATION OF APP EXPRESSION AS A THERAPEUTIC APPROACH FOR AMYLOID PATHOLOGIES
WO2023081500A2 (en) * 2021-11-08 2023-05-11 Dicerna Pharmaceuticals, Inc. RNAi OLIGONUCLEOTIDE CONJUGATES
TW202335674A (zh) * 2021-11-05 2023-09-16 美商黛瑟納製藥公司 靶定中樞神經系統的星狀細胞之脂質結合物
WO2023173061A2 (en) * 2022-03-11 2023-09-14 University Of Massachusetts Oligonucleotides for app modulation
WO2023207615A1 (zh) * 2022-04-26 2023-11-02 南京明德新药研发有限公司 一类含由天然核苷酸组成突出端的双链RNAi化合物
WO2023224979A1 (en) * 2022-05-16 2023-11-23 University Of Massachusetts Optimized sirna scaffolds
WO2023230465A1 (en) * 2022-05-23 2023-11-30 Switch Therapeutics Inc. Antisense oligonucleotides
WO2025007961A1 (zh) 2023-07-06 2025-01-09 大睿生物 调控AGT表达的dsRNA分子
US20250064958A1 (en) * 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025045195A1 (zh) * 2023-08-31 2025-03-06 上海拓界生物医药科技有限公司 靶向APP的RNAi剂及其医药用途
AU2024354107A1 (en) * 2023-09-28 2026-04-16 Bebetter Med Inc. Sirna inhibiting expression of amyloid precursor protein (app) gene, drug, and use
TW202516009A (zh) * 2023-10-10 2025-04-16 大陸商上海舶望製藥有限公司 抑制澱粉樣前體蛋白(app)表達的組合物和方法
WO2025228429A1 (zh) * 2024-04-30 2025-11-06 北京安龙生物医药有限公司 靶向淀粉样前体蛋白基因的寡核苷酸及其用途
CN118979036B (zh) * 2024-08-01 2025-08-19 北京尧景基因技术有限公司 抑制APP基因表达的siRNA及其缀合物和应用
WO2026085164A2 (en) 2024-10-16 2026-04-23 Alnylam Pharmaceuticals, Inc. Snca irna formulations and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US8101348B2 (en) 2002-07-10 2012-01-24 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA-interference by single-stranded RNA molecules
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
CA2528963A1 (en) * 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
GB0324854D0 (en) * 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
EP1937066A4 (en) * 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
JP5252622B2 (ja) * 2007-01-17 2013-07-31 独立行政法人産業技術総合研究所 高いヌクレアーゼ耐性と優れたｒｎａ干渉効果を発現可能な二本鎖ｒｎａ
JP5683261B2 (ja) * 2008-03-11 2015-03-11 学校法人 埼玉医科大学 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
EP2862929B1 (en) * 2009-12-09 2017-09-06 Quark Pharmaceuticals, Inc. Compositions and methods for treating diseases, disorders or injury of the CNS
JP2013541510A (ja) * 2010-08-31 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
WO2013180038A1 (ja) * 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
IL292159B1 (en) * 2012-12-05 2026-04-01 Alnylam Pharmaceuticals Inc PCSK9 iRNA compositions and methods of using them
US10004814B2 (en) * 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
TW202503057A (zh) * 2014-10-10 2025-01-16 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
KR102545316B1 (ko) * 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
AU2016337034A1 (en) * 2015-10-16 2018-05-10 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for use in treating Alzheimer's disease
MX2020011570A (es) * 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
WO2020160163A1 (en) * 2019-01-29 2020-08-06 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression
EP3983077A4 (en) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM

Similar Documents

Publication Publication Date Title
JP2022515193A5 (https=)
CN113454222B (zh) 淀粉样前体蛋白(APP)RNAi剂组成物及其使用方法
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
TWI727917B (zh) ＴＭＰＲＳＳ６ｉＲＮＡ 組成物及其使用方法
TWI727963B (zh) 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其治療或預防ＴＴＲ相關疾病之使用方法
CN115397436B (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
TW201726148A (zh) 治療ｓｅｒｐｉｎｃ１相關疾患之方法及組成物
EA035756B1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
JP2022520986A5 (https=)
KR20220069103A (ko) 최소 플루오린 함량을 갖는 작은 간섭 rna의 화학적 변형
TW202132567A (zh) 亨汀頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
JP2024536811A5 (https=)
JP2023523993A5 (https=)
JP2024528503A5 (https=)
WO2023116607A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2023544413A5 (https=)
JP2023511434A5 (https=)
IL294728A (en) lrrk2 RNA material preparations and methods of using them
TW202305134A (zh) 杭丁頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
JP2024522068A5 (https=)
TW202400193A (zh) 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
WO2021157730A1 (ja) 核酸医薬とその使用
CN118974069A (zh) 一种核酸缀合物、制备方法及用途
JP2024521907A5 (https=)
CN120813691A (zh) Reversir分子及其使用方法